Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
GSK Seeks Label Expansion of Arexvy for High-Risk Adults Aged 50-59
GlaxoSmithKline said on December 12 that it has filed a regulatory application in Japan seeking an additional indication of its respiratory syncytial virus (RSV) vaccine Arexvy for the prevention of RSV disease in adults aged 50-59 at increased risk. In…
To read the full story
Related Article
BUSINESS
- Nipro Grabs Japan Approval for Stelara IV Biosimilar
September 4, 2026
- Leqembi Subcutaneous Autoinjector Approved in China
September 4, 2026
- Halaven Generics Obtain Soft Tissue Sarcoma Use
September 3, 2026
- Ono Teams with Aitia in AI-Driven Neurology Drug Discovery
September 3, 2026
- Nippon Kayaku’s Generic Sunitinib Gains Pancreatic NET Use
September 3, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…